David Polsky

List of Publications by Year
in descending order

157 papers	7,991 citations	53751 45 h-index	49868 87 g-index
157 all docs	157 docs citations	157 times ranked	9308 citing authors

#	Article	IF	Citations
1	Melanoma surveillance for high-risk patients via telemedicine: Examination of real-world data from an integrated store-and-forward total body photography and dermoscopy service. Journal of the American Academy of Dermatology, 2022, 86, 191-192.	0.6	4
2	Differentiating Between Lead-Time Bias and True Survival Benefits When Discussing Racial and Ethnic Disparities in Melanoma. JAMA Dermatology, 2022, , .	2.0	0
3	Associations between TERT Promoter Mutations and Survival in Superficial Spreading and Nodular Melanomas in a Large Prospective Patient Cohort. Journal of Investigative Dermatology, 2022, 142, 2733-2743.e9.	0.3	7
4	Patient- and County-Level Factors Associated with Late-Stage Merkel Cell Carcinoma at Diagnosis. Journal of Investigative Dermatology, 2022, 142, 3113-3117.	0.3	0
5	Cell-Free DNA in Dermatology Research. Journal of Investigative Dermatology, 2022, 142, 1523-1528.e1.	0.3	2
6	Real-world outcomes of melanoma surveillance using the MoleMap NZ telemedicine platform. Journal of the American Academy of Dermatology, 2021, 85, 596-603.	0.6	8
7	MC1R variants in relation to naevi in melanoma cases and controls: a pooled analysis from the Mâ€SKIP project. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e135-e138.	1.3	3
8	Utility of confocal microscopy in the management of lentigo maligna and lentigo maligna melanoma. Journal of the American Academy of Dermatology, 2021, 84, 1736-1737.	0.6	0
9	Dermoscopy Proficiency Expectations for US Dermatology Resident Physicians. JAMA Dermatology, 2021, 157, 189.	2.0	4
10	Impact of COVID-19 on melanoma diagnosis. Melanoma Research, 2021, 31, 280-281.	0.6	18
11	Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. Lancet Oncology, The, 2021, 22, 370-380.	5.1	57
12	Melanoma origins: data from earlyâ€stage tumours supports de novo and naevusâ€associated melanomas as distinct subtypes. British Journal of Dermatology, 2021, 185, 9-10.	1.4	0
13	Late-Stage Melanoma in New York State: Associations with Socioeconomic Factors and Healthcare Access at the County Level. Journal of Investigative Dermatology, 2021, 141, 1699-1706.e7.	0.3	9
14	An irregular black patch on the nail plate. JAAD Case Reports, 2020, 6, 1069-1071.	0.4	0
15	Prognostic Gene Expression Profiling in Cutaneous Melanoma. JAMA Dermatology, 2020, 156, 1004.	2.0	59
16	MC1R variants and cutaneous melanoma risk according to histological type, body site, and Breslow thickness: a pooled analysis from the M-SKIP project. Melanoma Research, 2020, 30, 500-510.	0.6	6
17	New Systematic Therapies and Trends in Cutaneous Melanoma Deaths Among US Whites, 1986â€“2016. American Journal of Public Health, 2020, 110, 731-733.	1.5	91
18	TERT, BRAF, and NRAS Mutational Heterogeneity between Paired Primary and Metastatic Melanoma Tumors. Journal of Investigative Dermatology, 2020, 140, 1609-1618.e7.	0.3	14

#	Article	IF	Citations
19	Melanoma Prognosis: Accuracy of the American Joint Committee on Cancer Staging Manual Eighth Edition. Journal of the National Cancer Institute, 2020, 112, 921-928.	3.0	32
20	Technological advances for the detection of melanoma. Journal of the American Academy of Dermatology, 2020, 83, 983-992.	0.6	29
21	Technological advances for the detection of melanoma. Journal of the American Academy of Dermatology, 2020, 83, 996-1004.	0.6	20
22	Validation of Circulating Tumor DNA Assays for Detection of Metastatic Melanoma. Methods in Molecular Biology, 2020, 2055, 155-180.	0.4	7
23	Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy. Journal of the National Cancer Institute, 2019, 111, 180-188.	3.0	74
24	Immunomodulatory germline variation associated with the development of multiple primary melanoma (MPM). Scientific Reports, 2019, 9, 10173.	1.6	6
25	MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort. The Lancet Child and Adolescent Health, 2019, 3, 332-342.	2.7	16
26	Towards Automated Melanoma Detection With Deep Learning: Data Purification and Augmentation. , 2019, , .		70
27	Impact of initial stage on metastatic melanoma survival. Melanoma Research, 2019, 29, 281-288.	0.6	12
28	Development of Novel Mutation-Specific Droplet Digital PCR Assays Detecting TERT Promoter Mutations in Tumor and Plasma Samples. Journal of Molecular Diagnostics, 2019, 21, 274-285.	1.2	46
29	Plasma cell-free circulating tumor DNA (ctDNA) detection in longitudinally followed glioblastoma patients using TERT promoter mutation-specific droplet digital PCR assays.. Journal of Clinical Oncology, 2019, 37, 2026-2026.	0.8	11
30	Circulating tumor DNA (ctDNA) kinetics to predict survival in patients (pts) with unresectable or metastatic melanoma treated with dabrafenib (D) or D + trametinib (T).. Journal of Clinical Oncology, 2019, 37, 9510-9510.	0.8	1
31	Abstract 4704: Identification of melanoma mutational tumor heterogeneity using BRAF, NRAS and TERT-promoter mutation-detection assays. , 2019, , .		0
32	Abstract 2239: Analysis of nucleosomal DNA as an extraction control for plasma-based circulating tumor DNA assays. , 2019, , .		1
33	Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM). Annals of Oncology, 2018, 29, viii21.	0.6	0
34	Acral Melanoma: A Patientâ€™s Experience and Physicianâ€™s Commentary. Dermatology and Therapy, 2018, 8, 503-507.	1.4	1
35	Comment on â€œPrognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanomaâ€• Journal of the American Academy of Dermatology, 2018, 79, e53-e54.	0.6	1
36	MC1R variants as melanoma risk factors independent of at-risk phenotypic characteristics: a pooled analysis from the M-SKIP project. Cancer Management and Research, 2018, Volume 10, 1143-1154.	0.9	57

#	Article	IF	Citations
37	Association between Kiâ€67 expression and clinical outcomes among patients with clinically nodeâ€negative, thick primary melanoma who underwent nodal staging. Journal of Surgical Oncology, 2018, 118, 150-156.	0.8	7
38	Bone metastasis to predict treatment response rate and overall survival of patients with metastatic melanoma.. Journal of Clinical Oncology, 2018, 36, e21585-e21585.	0.8	2
39	Abstract 5534: Analysis ofTERTmutantcirculating tumor DNA as a potential biomarker of disease activity in patients with unresectable stage III/IV melanoma receiving immuno-oncology therapies. , 2018, , .		1
40	Abstract 5531: Detection of co-occurring and potential resistance mutations in cell-free, circulating tumor DNA from patients withBRAFmutantmetastatic melanoma undergoing treatment with BRAF-targeted therapies. , 2018, , .		0
41	Dermoscopic features of a solitary fibrofolliculoma on the left cheek. Journal of the American Academy of Dermatology, 2017, 76, S8-S9.	0.6	7
42	A prospective study evaluating the utility of a 2-mm biopsy margin for complete removal of histologically atypical (dysplastic) nevi. Journal of the American Academy of Dermatology, 2017, 77, 1096-1099.	0.6	5
43	Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care. Oncology, 2017, 93, 164-176.	0.9	6
44	214 A growing mortality epidemic among white men ages 50+: Time to find intersections for a targeted national melanoma screening program. Journal of Investigative Dermatology, 2017, 137, S36.	0.3	0
45	Mole Mapping for Management of Pigmented Skin Lesions. Dermatologic Clinics, 2017, 35, 439-445.	1.0	21
46	Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma. Journal of the American Academy of Dermatology, 2017, 76, 114-120.e2.	0.6	107
47	Novel germline risk loci in familial melanoma (FM).. Journal of Clinical Oncology, 2017, 35, 1535-1535.	0.8	0
48	A 'melanoma mortality belt' of ten U.S. states with the highest melanoma mortality rates.. Journal of Clinical Oncology, 2017, 35, e21039-e21039.	0.8	0
49	Accelerated melanoma mortality rates among middle-aged white males with tumors of all thicknesses.. Journal of Clinical Oncology, 2017, 35, e21029-e21029.	0.8	0
50	Abstract 743: Detection of TERT C228T and C250T promoter mutations in melanoma tumor and plasma samples using novel mutation-specific droplet digital PCR assays. , 2017, , .		1
51	De Novo vs Nevus-Associated Melanomas: Differences in Associations With Prognostic Indicators and Survival. Journal of the National Cancer Institute, 2016, 108, djw121.	3.0	67
52	Association of Melanocortin-1 Receptor Variants with Pigmentary Traits in Humans: AÂPooled Analysis from the M-Skip Project. Journal of Investigative Dermatology, 2016, 136, 1914-1917.	0.3	16
53	Acral melanocytic lesions in the United States: Prevalence, awareness, and dermoscopic patterns in skin-of-color and non-Hispanic white patients. Journal of the American Academy of Dermatology, 2016, 74, 724-730.e1.	0.6	39
54	Impact of Socioeconomic Status and Ethnicity on Melanoma Presentation and Recurrence in Caucasian Patients. Oncology, 2016, 90, 79-87.	0.9	10

#	Article	IF	Citations
55	Sensitivity of plasma BRAF^{mutant} and NRAS^{mutant} cellâ€free DNA assays to detect metastatic melanoma in patients with low RECIST scores and nonâ€RECIST disease progression. Molecular Oncology, 2016, 10, 157-165.	2.1	63
56	Metastatic melanoma outcomes in the era of commercially available targeted therapy and immunotherapy.. Journal of Clinical Oncology, 2016, 34, e21017-e21017.	0.8	0
57	Prognostic value of mitoses in thick primary melanoma.. Journal of Clinical Oncology, 2016, 34, e21046-e21046.	0.8	0
58	The impact of clinical stage at primary melanoma diagnosis on post-recurrence survival.. Journal of Clinical Oncology, 2016, 34, 9550-9550.	0.8	0
59	Analysis of TERT promoter mutations, polymorphisms, clinicopathologic features and recurrence-free survival in primary melanoma.. Journal of Clinical Oncology, 2016, 34, e21065-e21065.	0.8	0
60	Somatic and germline analyses of a long term melanoma survivor with a recurrent brain metastasis. BMC Cancer, 2015, 15, 926.	1.1	2
61	Sustaining the Rheumatology Research Enterprise. Arthritis Care and Research, 2015, 67, 1187-1190.	1.5	5
62	Genetic associations of the interleukin locus at 1q32.1 with clinical outcomes of cutaneous melanoma. Journal of Medical Genetics, 2015, 52, 231-239.	1.5	17
63	Skin cancer risk inBRCA1/2mutation carriers. British Journal of Dermatology, 2015, 172, 1498-1506.	1.4	45
64	Acral Lentiginous Melanoma of the Foot Misdiagnosed as a Traumatic Ulcer. Journal of the American Podiatric Medical Association, 2015, 105, 189-194.	0.2	9
65	Polarized light dermoscopy to aid in the diagnosis of new pink lesions in an amelanotic melanoma survivor. Journal of the American Academy of Dermatology, 2015, 73, e197-e199.	0.6	1
66	Mutational Heterogeneity in Melanoma: An Inconvenient Truth. Journal of Investigative Dermatology, 2015, 135, 2913-2918.	0.3	8
67	Examining the scalp for melanoma? Try a blow dryer. Journal of the American Academy of Dermatology, 2015, 73, e211.	0.6	0
68	The impact of primary melanoma histotype on overall survival and response to immunotherapy.. Journal of Clinical Oncology, 2015, 33, e20078-e20078.	0.8	0
69	Impact of socioeconomic status (SES) and ethnicity on melanoma presentation and recurrence in Caucasian patients.. Journal of Clinical Oncology, 2015, 33, e20098-e20098.	0.8	0
70	De novo versus nevus-associated melanomas: Differences in associations with prognostic indicators and survival.. Journal of Clinical Oncology, 2015, 33, 9025-9025.	0.8	0
71	Abstract A31: Association between TERT promoter mutations and BRAF/NRAS mutations in patients with primary and metastatic melanoma tumors. , 2015, , .		0
72	Abstract 4627: A novel computational re-analysis of published GWAS data suggests new risk loci for melanoma susceptibility. , 2015, , .		0

#	Article	IF	Citations
73	Abstract 4628: Analysis of melanoma GWAS data suggests specific risk loci influencing age of onset of melanoma. , 2015, , .		0
74	Vulvar nevi, melanosis, and melanoma: An epidemiologic, clinical, and histopathologic review. Journal of the American Academy of Dermatology, 2014, 71, 1241-1249.	0.6	77
75	More Skin, More Sun, More Tan, More Melanoma. American Journal of Public Health, 2014, 104, e92-e99.	1.5	58
76	Germline genetic determinants of immunotherapy response in metastatic melanoma.. Journal of Clinical Oncology, 2014, 32, 3004-3004.	0.8	6
77	Development of a Melanoma Risk Prediction Model Incorporating MC1R Genotype and Indoor Tanning Exposure: Impact of Mole Phenotype on Model Performance. PLoS ONE, 2014, 9, e101507.	1.1	14
78	The genetic variants in interleukin locus at 1q32.1 as markers of melanoma survival.. Journal of Clinical Oncology, 2014, 32, 9094-9094.	0.8	0
79	Droplet digital PCR monitoring of BRAF and NRAS plasma DNA as biomarkers of treatment response in stage IV melanoma.. Journal of Clinical Oncology, 2014, 32, 9019-9019.	0.8	0
80	Abstract 2847: Quantitative assessment of circulating BRAF DNA in stage IV melanoma patients undergoing BRAF inhibitor treatment. , 2014, , .		0
81	The importance of dedicated dermoscopy training during residency: A survey of US dermatology chief residents. Journal of the American Academy of Dermatology, 2013, 68, 1000-1005.	0.6	27
82	Melanoma risk loci as determinants of melanoma recurrence and survival. Journal of Translational Medicine, 2013, 11, 279.	1.8	30
83	Impact of Age on the Management of Primary Melanoma Patients. Oncology, 2013, 85, 173-181.	0.9	14
84	Cyclo-oxygenase-2 inhibitors for chemoprevention of nonmelanoma skin cancer: Is there a role for these agents?. Journal of the American Academy of Dermatology, 2013, 68, 173-176.	0.6	11
85	Mitotic Rate in Melanoma. American Journal of Surgical Pathology, 2013, 37, 882-889.	2.1	36
86	Abstract 2288: Improving melanoma risk prediction among individuals with low-risk mole phenotypes.. , 2013, , .		0
87	Impact of age on treatment of primary melanoma patients.. Journal of Clinical Oncology, 2013, 31, 9054-9054.	0.8	0
88	Analysis of plasma-based BRAF and NRAS mutation detection in patients with stage III and IV melanoma.. Journal of Clinical Oncology, 2013, 31, 9023-9023.	0.8	0
89	Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma. PLoS ONE, 2012, 7, e29336.	1.1	250
90	Botulinum Toxin-A for the Treatment of Raynaud Syndrome. Archives of Dermatology, 2012, 148, 426.	1.7	34

#	Article	IF	Citations
91	Agreement of Dermatopathologists in the Evaluation of Clinically Difficult Melanocytic Lesions: How Golden Is the Â‘Gold StandardÂ’?. Dermatology, 2012, 224, 51-58.	0.9	45
92	Development of a melanoma riskÂprediction modelÂincorporating MC1R genotype and indoor tanning exposure.. Journal of Clinical Oncology, 2012, 30, 8574-8574.	0.8	9
93	Prognostic value of mitosis-specific antibodies and computer image analysisÂin calculatingÂmitotic rateÂin melanoma.. Journal of Clinical Oncology, 2012, 30, e19003-e19003.	0.8	0
94	Analysis of the Benign to Malignant Ratio of Lesions Biopsied by a General Dermatologist Before and After the Adoption of Dermoscopy. Archives of Dermatology, 2011, 146, 343-4.	1.7	36
95	Noninvasive genomic detection of melanoma. British Journal of Dermatology, 2011, 164, 797-806.	1.4	92
96	Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and postâ€brain metastases survival. Cancer, 2011, 117, 1711-1720.	2.0	83
97	A High Proliferative Index of Recurrent Melanoma Is Associated with Worse Survival. Oncology, 2011, 80, 181-187.	0.9	17
98	Integrative Genomics Identifies Molecular Alterations that Challenge the Linear Model of Melanoma Progression. Cancer Research, 2011, 71, 2561-2571.	0.4	57
99	Dysplastic Nevi. , 2011, , 231-245.		0
100	The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature, 2010, 468, 1105-1109.	13.7	345
101	A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue Correlates. PLoS ONE, 2010, 5, e15588.	1.1	90
102	Association Between Thin Melanomas and Atypical Nevi in Middle-aged and Older Men Possibly Attributable to Heightened Patient Awareness. Archives of Dermatology, 2009, 145, 1457-8.	1.7	0
103	Phosphorylated 4E-BP1 Is Associated with Poor Survival in Melanoma. Clinical Cancer Research, 2009, 15, 2872-2878.	3.2	62
104	Association of MDM2 SNP309, Age of Onset, and Gender in Cutaneous Melanoma. Clinical Cancer Research, 2009, 15, 2573-2580.	3.2	36
105	Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 1814-1819.	3.3	506
106	Metaâ€analysis of sentinel lymph node positivity in thin melanoma (â‰¤1 mm). Cancer, 2009, 115, 869-879.	2.0	105
107	Evaluation of the melanocortin-1-receptor gene in melanoma predisposition, progression, and recurrence. Journal of Clinical Oncology, 2009, 27, 9018-9018.	0.8	0
108	Detection of BRAF kinase mutations in melanoma, ovarian, and prostate carcinomas: Evidence for tumor heterogeneity in clinical samples. Journal of Clinical Oncology, 2009, 27, 11031-11031.	0.8	1

#	Article	IF	Citations
109	Developing genetic markers for melanoma risk assessment. Journal of Clinical Oncology, 2009, 27, 9046-9046.	0.8	0
110	The unique molecular signatures of nodular and superficial spreading melanoma. Journal of Clinical Oncology, 2009, 27, 9047-9047.	0.8	0
111	Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research. American Journal of Translational Research (discontinued), 2009, 1, 35-43.	0.0	33
112	Changes in the presentation of nodular and superficial spreading melanomas over 35 years. Cancer, 2008, 113, 3341-3348.	2.0	78
113	Nucleofection is a highly effective gene transfer technique for human melanoma cell lines. Experimental Dermatology, 2008, 17, 405-411.	1.4	10
114	Assessing the clinical utility of measuring Insulin-like Growth Factor Binding Proteins in tissues and sera of melanoma patients. Journal of Translational Medicine, 2008, 6, 70.	1.8	10
115	Tinea versicolor associated with etanercept therapy. Journal of the American Academy of Dermatology, 2008, 58, S99-S100.	0.6	11
116	Frequent p16-Independent Inactivation of p14ARF in Human Melanoma. Journal of the National Cancer Institute, 2008, 100, 784-795.	3.0	94
117	CASH Algorithm for Dermoscopy Revisited. Archives of Dermatology, 2008, 144, 554-5.	1.7	20
118	Utility of Lesion Diameter in the Clinical Diagnosis of Cutaneous Melanoma. Archives of Dermatology, 2008, 144, 469-74.	1.7	52
119	The Diagnostic Performance of Expert Dermoscopists vs a Computer-Vision System on Small-Diameter Melanomas. Archives of Dermatology, 2008, 144, 476-82.	1.7	78
120	Shedding of Distinct Cryptic Collagen Epitope (HU177) in Sera of Melanoma Patients. Clinical Cancer Research, 2008, 14, 6253-6258.	3.2	16
121	Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma. Clinical Cancer Research, 2008, 14, 8302-8307.	3.2	193
122	Tumor heterogeneity: Evidence from BRAF V600E mutation detection. Journal of Clinical Oncology, 2008, 26, 20022-20022.	0.8	1
123	Neutrophilic eccrine hidradenitis masquerading asÂfacial cellulitis. Journal of the American Academy of Dermatology, 2007, 56, 693-696.	0.6	21
124	The CASH (color, architecture, symmetry, and homogeneity) algorithm for dermoscopy. Journal of the American Academy of Dermatology, 2007, 56, 45-52.	0.6	203
125	Dermoscopy Key Points: Recommendations from the International Dermoscopy Society. Dermatology, 2007, 214, 3-5.	0.9	58
126	Detection of Mutant BRAF Alleles in the Plasma of Patients with Metastatic Melanoma. Journal of Molecular Diagnostics, 2007, 9, 178-183.	1.2	40

#	Article	IF	Citations
127	Clinical relevance of neutral endopeptidase (NEP/CD10) in melanoma. Journal of Translational Medicine, 2007, 5, 2.	1.8	29
128	Role of radiologic imaging at the time of initial diagnosis of stage T1bâ€T3b melanoma. Cancer, 2007, 110, 1107-1114.	2.0	93
129	â€œFat fingers:â€•A clue in the dermoscopic diagnosis ofÂseborrheic keratoses. Journal of the American Academy of Dermatology, 2006, 55, 1089-1091.	0.6	39
130	In Consideration of the E in the Melanoma ABCDE Mnemonicâ€”Reply. Archives of Dermatology, 2006, 142, 529.	1.7	0
131	A phase II trial of BAY 43â€“9006 in metastatic melanoma with molecularly characterized B-Raf status. Journal of Clinical Oncology, 2006, 24, 8046-8046.	0.8	1
132	Clinical relevance of neutral endopeptidase overexpression in melanoma. Journal of Clinical Oncology, 2006, 24, 8028-8028.	0.8	0
133	Altered patterns of RB expression define groups of soft tissue sarcoma patients with distinct biological and clinical behavior. Histology and Histopathology, 2006, 21, 743-52.	0.5	7
134	Association of melanoma and neurocutaneous melanocytosis with large congenital melanocytic naevi-results from the NYU-LCMN registry. British Journal of Dermatology, 2005, 152, 512-517.	1.4	176
135	Evaluation of germline CDKN2A, ARF, CDK4, PTEN, and BRAF alterations in atypical mole syndrome. Clinical and Experimental Dermatology, 2005, 30, 68-70.	0.6	23
136	ABCDEâ€”An Evolving Concept in the Early Detection of Melanoma. Archives of Dermatology, 2005, 141, 1032-4.	1.7	149
137	PTEN Expression in Melanoma: Relationship with Patient Survival, Bcl-2 Expression, and Proliferation. Clinical Cancer Research, 2005, 11, 5153-5157.	3.2	81
138	The ABCDEs of melanoma: an evolving concept. Journal of Drugs in Dermatology, 2005, 4, 399-401.	0.4	0
139	Early Diagnosis of Cutaneous Melanoma. JAMA - Journal of the American Medical Association, 2004, 292, 2771.	3.8	506
140	Altered N-myc Downstream-Regulated Gene 1 Protein Expression in African-American Compared with Caucasian Prostate Cancer Patients. Clinical Cancer Research, 2004, 10, 222-227.	3.2	40
141	Clinical significance of BRAF mutations in metastatic melanoma. Journal of Translational Medicine, 2004, 2, 46.	1.8	58
142	Detection of melanomas in patients followed up with total cutaneous examinations, total cutaneous photography, and dermoscopy. Journal of the American Academy of Dermatology, 2004, 50, 15-20.	0.6	60
143	Explaining differences in chemotherapy utilization in ovarian cancer between health service areas. Journal of Clinical Oncology, 2004, 22, 6005-6005.	0.8	0
144	Oncogenes in melanoma. Oncogene, 2003, 22, 3087-3091.	2.6	107

#	Article	IF	Citations
145	Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Research, 2003, 63, 3955-7.	0.4	177
146	HDM2 Protein Overexpression and Prognosis in Primary Malignant Melanoma. Journal of the National Cancer Institute, 2002, 94, 1803-1806.	3.0	74
147	Focus on melanoma. Cancer Cell, 2002, 2, 275-278.	7.7	225
148	Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanoma. Cancer, 2002, 95, 634-640.	2.0	50
149	Reduction of ultraviolet transmission through cotton t-shirt fabrics with low ultraviolet protection by various laundering methods and dyeing: Clinical implications. Journal of the American Academy of Dermatology, 2001, 44, 767-774.	0.6	92
150	Ultraviolet A and melanoma: A review. Journal of the American Academy of Dermatology, 2001, 44, 837-846.	0.6	379
151	High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas. Cancer, 2001, 92, 869-874.	2.0	89
152	Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature, 2001, 409, 207-211.	13.7	901
153	The transcriptional repressor of p16/Ink4a, Id1, is up-regulated in early melanomas. Cancer Research, 2001, 61, 6008-11.	0.4	77
154	HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Research, 2001, 61, 7642-6.	0.4	94
155	HMO penetration and the geographic mobility of practicing physicians. Journal of Health Economics, 2000, 19, 793-809.	1.3	17
156	Cooperative effects of INK4a and ras in melanoma susceptibility inâ€‰vivo. Genes and Development, 1997, 11, 2822-2834.	2.7	366
157	Suppression of H-2b-associated resistance to Friend erythroleukemia virus by a class I gene from the H-2d major histocompatibility complex haplotype.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 9243-9247.	3.3	17